Clinical trial · Interventional
Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies
NCT02683538CI-TRIAL-00021637completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the clinical feasibility and short-term outcome of switching monopolar RFA using a separable cluster electrode in patients with primary and secondary liver malignancies.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Separable cluster electrode (Octopus®) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Separable cluster electrode
- description
- radiofrequency ablation (RFA) using separable cluster electrode in switching monopolar mode.
- interventionNames
- Device: Separable cluster electrode (Octopus®)
Primary outcomes (1)
- measure
- Major complication rate after Radiofrequency ablation (RFA)
- timeFrame
- 30 days after RFA
- description
- Rates of major complication according to Society of Interventional Radiology (SIR) grading system, which refers to an event that leads to substantial morbidity and disability (SIR classification C-E).
Secondary outcomes (2)
- measure
- Technical success
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Hepatic malignancies diagnosed on biopsy OR * Typical imaging features of hepatocellular carcinoma (HCC) on computed tomography (CT) or magnetic resonance imaging (MRI) according to AASLD guideline * Typical imaging feature of metastasis on CT or MRI AND * 1\~5 tumors equal to or smaller than 5cm in the liver * no direct contact with or invasion into the hepatic hilar structures or inferior vena cava (IVC) * Eastern Cooperative Oncology Group performance status of 0 * Patients who signed informed consent Exclusion Criteria: Patients with any of followings are excluded. * Patients with uncontrolled coagulopathy * Patients with Child-Pugh classification C * Patients with tumor invasion in major portal vein or hepatic vein branch * Extrahepatic metastasis
References
Publications (0)
Data not yet available
No reference posted for this study.